文献
J-GLOBAL ID:201702219275408629
整理番号:17A1189386
再発性または難治性の慢性リンパ性白血病におけるVenetoclax+リツキシマブ:第1b相試験【Powered by NICT】
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
著者 (31件):
Seymour John F
(Peter MacCallum Cancer Centre, Melbourne, VIC, Australia)
,
Seymour John F
(Victorian Comprehensive Cancer Centre, Parkville, Melbourne, VIC, Australia)
,
Seymour John F
(Faculty of Medicine, University of Melbourne, Parkville, Melbourne, VIC, Australia)
,
Ma Shuo
(Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA)
,
Brander Danielle M
(Duke University Medical Center, Durham, NC, USA)
,
Choi Michael Y
(University of California San Diego, San Diego, CA, USA)
,
Barrientos Jacqueline
(Hofstra Northwell School of Medicine, Hempstead, NY, USA)
,
Davids Matthew S
(Dana-Farber Cancer Institute, Boston, MA, USA)
,
Anderson Mary Ann
(Department of Clinical Haematology and BMT, The Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia)
,
Anderson Mary Ann
(Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia)
,
Beaven Anne W
(Duke University Medical Center, Durham, NC, USA)
,
Rosen Steven T
(City of Hope National Medical Center, Duarte, CA, USA)
,
Tam Constantine S
(Peter MacCallum Cancer Centre, Melbourne, VIC, Australia)
,
Tam Constantine S
(Victorian Comprehensive Cancer Centre, Parkville, Melbourne, VIC, Australia)
,
Tam Constantine S
(Faculty of Medicine, University of Melbourne, Parkville, Melbourne, VIC, Australia)
,
Prine Betty
(AbbVie, Inc, North Chicago, IL, USA)
,
Agarwal Suresh K
(AbbVie, Inc, North Chicago, IL, USA)
,
Munasinghe Wijith
(AbbVie, Inc, North Chicago, IL, USA)
,
Zhu Ming
(AbbVie, Inc, North Chicago, IL, USA)
,
Lash L Leanne
(AbbVie, Inc, North Chicago, IL, USA)
,
Desai Monali
(AbbVie, Inc, North Chicago, IL, USA)
,
Cerri Elisa
(AbbVie, Inc, North Chicago, IL, USA)
,
Verdugo Maria
(AbbVie, Inc, North Chicago, IL, USA)
,
Kim Su Young
(AbbVie, Inc, North Chicago, IL, USA)
,
Humerickhouse Rod A
(AbbVie, Inc, North Chicago, IL, USA)
,
Gordon Gary B
(AbbVie, Inc, North Chicago, IL, USA)
,
Kipps Thomas J
(University of California San Diego, San Diego, CA, USA)
,
Roberts Andrew W
(Victorian Comprehensive Cancer Centre, Parkville, Melbourne, VIC, Australia)
,
Roberts Andrew W
(Faculty of Medicine, University of Melbourne, Parkville, Melbourne, VIC, Australia)
,
Roberts Andrew W
(Department of Clinical Haematology and BMT, The Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia)
,
Roberts Andrew W
(Division of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia)
資料名:
Lancet Oncology
(Lancet Oncology)
巻:
18
号:
2
ページ:
230-240
発行年:
2017年
JST資料番号:
W1266A
ISSN:
1470-2045
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)